Conference Coverage

Complete Conference Coverage

High Tissue Tumor Mutational Burden May Be Predictive of Improved Immunotherapy Efficacy

High Tissue Tumor Mutational Burden May Be Predictive of Improved Immunotherapy Efficacy

Data from previous studies evaluating the efficacy of atezolizumab, a PD-L1 inhibitor, have suggested that high tissue tumor mutational burden may be predictive of efficacy for checkpoint immunotherapy.

Adding Oxaliplatin to Capecitabine-Based Chemotherapy, Radiation May Not Improve Survival in Rectal Cancer

Adding Oxaliplatin to Capecitabine-Based Chemotherapy, Radiation May Not Improve Survival in Rectal Cancer

Researchers randomly assigned 1090 patients with advanced rectal adenocarcinoma to 5 weeks of preoperative capecitabine-based chemoradiation followed by 6 cycles of capecitabine alone or with oxaliplatin.

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

Nivolumab Plus Ipilimumab May Improve 2-Year Quality of Life in Advanced Renal Cell Carcinoma

Findings previously demonstrated that nivolumab plus ipilimumab prolongs overall survival and was better tolerated among patients with renal cell carcinoma, but its impact on health-related quality of life was not reported.

mFOLFIRINOX After Resection May Lead to Improved Outcomes in Pancreatic Carcinoma

mFOLFIRINOX After Resection May Lead to Improved Outcomes in Pancreatic Carcinoma

Previous studies demonstrated that FOLFIRINOX is more effective than gemcitabine as first-line treatment for patients with metastatic pancreatic cancer with good performance status.

Chemoradiotherapy Before Surgery May Improve Outcomes in Resectable Pancreatic Cancer

Chemoradiotherapy Before Surgery May Improve Outcomes in Resectable Pancreatic Cancer

Evidence suggests that neoadjuvant chemoradiotherapy may afford benefit, but this hypothesis requires further validation.

Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer

Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer

Recent studies have explored the potential of combination therapy with EGFR-TKIs and VEGF-inhibitors for patients with EGFR-positive non-small cell lung cancer.

Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in EGFR-Positive NSCLC

Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in EGFR-Positive NSCLC

EGFR tyrosine kinase inhibitor monotherapy has improved progression-free survival (PFS) but not overall survival (OS) compared with chemotherapy in non-small cell lung cancer.

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.

Prostate Cancer Vaccine Found Not To Improve Survival

Prostate Cancer Vaccine Found Not To Improve Survival

In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs